Zenas BioPharma, Inc.

NASDAQ:ZBIO

Biotechnology

Healthcare
$26.42 +3.46%

+$0.64 today

Market cap
$1.79B
Beta
-0.69
P/E (TTM)
-2.5
EPS (TTM)
-$7.64
52W Low $8.91High $44.60

Volume 0.48M

Average 0.71M

ZBIO Debt Repayment

Cash used to repay borrowings during the period.

Zenas BioPharma, Inc.NASDAQ: ZBIO

Debt Repayment · Q1 FY2026 · quarter ended Mar 2026

Debt repayment outflow grows to $267.03M

Q1 FY2026 debt repayment was $267.03M, compared with $0 a year earlier. Trailing-twelve-month debt repayment was $267.03M.

Context

  • Debt repayment amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Debt repayment increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly debt repayment holds near $267.03M or moves back toward the trailing-twelve-month quarterly average of $66.76M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$267.03M— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$267.03M— YoY
Debt Repayment past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Debt Repayment history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
—

Debt Repayment vs competitors

How ZBIO compares with its peers on the latest reported figures

  • ZBIO's LTM Mar 2026 debt repayment of $267.03M is the largest of the 8 companies compared; the peer median is $0.
ZBIO Competitors Peer median
Debt Repayment for ZBIO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ZBIOZenas BioPharma, Inc.LTM Mar 2026$267.03M ———
QTTBQ32 Bio Inc.LTM Mar 2026$4.69M ——8.7%
IMVTImmunovant, Inc.LTM Sep 2026$0 ——0.0%
TRAXFirst Tracks Biotherapeutics IncFY2025$0 ———
ANNXAnnexon, Inc.LTM Mar 2026$0 ———
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$0 ——0.0%
UPBUpstream Bio, Inc.LTM Mar 2026$0 ——0.0%
TLSATiziana Life Sciences LtdFY2025$0 +100.0%——
Peer median (excluding ZBIO) $0+100.0%—0.0%

Competitors are the stored peer set for ZBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(119.28M)(37.12M)(156.99M)(377.74M)
Depreciation & Amortization78K113K137K(1.88M)
Deferred Income Tax0000
Stock-Based Compensation737K3.5M10.82M26.35M
Change in Working Capital7.97M(8.04M)25.43M951K
Accounts Receivables0000
Inventory0000
Accounts Payables1.09M(418K)11.74M(10.04M)
Other Working Capital6.88M(7.62M)13.69M10.99M
Other Non-Cash Items44.85M11.03M925K179.98M
Operating Cash Flow(65.65M)(30.53M)(119.67M)(172.33M)
Capital Expenditures(2.2M)(17K)(131K)(18K)
Acquisitions (Net)0000
Purchases of Investments00(36.42M)(417.76M)
Sales of Investments006M200.89M
Other Investing Activities(2M)00(35M)
Investing Cash Flow(2.2M)(17K)(30.55M)(251.89M)
Debt Repayment020M00
Common Stock Issued59.39M116K240.64M152.95M
Common Stock Repurchased0000
Dividends Paid0000
Other Financing Activities00(6.06M)62.34M
Financing Cash Flow59.39M20.12M412.96M215.28M
Effect of Forex Changes(41K)78K157K(252K)
Net Change in Cash(8.5M)(10.35M)262.89M(209.19M)
Free Cash Flow(67.85M)(30.55M)(119.81M)(172.35M)

Zenas BioPharma, Inc.

NASDAQ:ZBIO

Intrinsic Alpha fair value

Locked

Current Price

$26.42

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.